Abeona Therapeutics - רווח לפני ניכוי ריבית, מסים, בלאי ופחת ABEO

Abeona Therapeutics (ABEO) develops breakthrough cellular patches for the therapy of rare skin and vision pathologies. The company's estimated EBITDA reflects cash flow dynamics before interest, where 0.00 represents the current metric. Production efficiency is increasing through AI models and the robotization of lines. The business is currently focusing on commercial scaling and refining the logistics for its first gene drug.

This indicator is calculated as the sum of operating profit and depreciation, excluding the impact of tax liabilities and debt service costs to identify the business's actual cash flow. For Abeona Therapeutics (ABEO), which is preparing to launch an orphan drug, the trend in gross operating profit before depreciation serves as a marker of financial resilience during the capacity build-up phase prior to receiving final regulatory approvals.